Please use this identifier to cite or link to this item: https://hdl.handle.net/10316/107784
DC FieldValueLanguage
dc.contributor.authorGuerreiro, Joana Fernandes-
dc.contributor.authorAlves, Vítor-
dc.contributor.authorAbrunhosa, Antero José-
dc.contributor.authorPaulo, António-
dc.contributor.authorGil, Octávia Monteiro-
dc.contributor.authorMendes, Filipa-
dc.date.accessioned2023-08-01T11:26:57Z-
dc.date.available2023-08-01T11:26:57Z-
dc.date.issued2018-11-11-
dc.identifier.issn1420-3049-
dc.identifier.urihttps://hdl.handle.net/10316/107784-
dc.description.abstract64CuCl₂ has recently been proposed as a promising agent for prostate cancer (PCa) theranostics, based on preclinical studies in cellular and animal models, and on the increasing number of human studies documenting its use for PCa diagnosis. Nevertheless, the use of 64CuCl₂ raises important radiobiological questions that have yet to be addressed. In this work, using a panel of PCa cell lines in comparison with a non-tumoral prostate cell line, we combined cytogenetic approaches with radiocytotoxicity assays to obtain significant insights into the cellular consequences of exposure to 64CuCl₂. PCa cells were found to exhibit increased 64CuCl₂ uptake, which could not be attributed to increased expression of the main copper cellular importer, hCtr1, as had been previously suggested. Early DNA damage and genomic instability were also higher in PCa cells, with the tumoral cell lines exhibiting deficient DNA-damage repair upon exposure to 64CuCl₂. This was corroborated by the observation that 64CuCl₂ was more cytotoxic in PCa cells than in non-tumoral cells. Overall, we showed for the first time that PCa cells had a higher sensitivity to 64CuCl₂ than healthy cells, supporting the idea that this compound deserved to be further evaluated as a theranostic agent in PCa.pt
dc.language.isoengpt
dc.publisherMDPIpt
dc.relationUID/Multi/04349/2013.pt
dc.rightsopenAccesspt
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt
dc.subjectcopper-64 chloridept
dc.subjecttheranosticspt
dc.subjectprostate cancept
dc.subjectradiobiologypt
dc.subjectauger therapypt
dc.titleRadiobiological Characterization of 64CuCl₂ as a Simple Tool for Prostate Cancer Theranosticspt
dc.typearticlept
degois.publication.firstPage2944pt
degois.publication.issue11pt
degois.publication.titleMoleculespt
dc.peerreviewedyespt
dc.identifier.doi10.3390/molecules23112944-
degois.publication.volume23pt
dc.date.embargo2018-11-11*
dc.identifier.pmid30423862-
uc.date.periodoEmbargo0pt
dc.identifier.eissn1420-3049-
item.grantfulltextopen-
item.cerifentitytypePublications-
item.languageiso639-1en-
item.openairetypearticle-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextCom Texto completo-
crisitem.author.researchunitICNAS - Institute for Nuclear Sciences Applied to Health-
crisitem.author.orcid0000-0002-4145-854X-
Appears in Collections:I&D ICNAS - Artigos em Revistas Internacionais
Show simple item record

SCOPUSTM   
Citations

14
checked on May 13, 2024

WEB OF SCIENCETM
Citations

13
checked on May 2, 2024

Page view(s)

52
checked on May 8, 2024

Download(s)

34
checked on May 8, 2024

Google ScholarTM

Check

Altmetric

Altmetric


This item is licensed under a Creative Commons License Creative Commons